Major news from #ASCO26: A multi-selective RAS(ON) inhibitor nearly doubles survival time in people with metastatic pancreatic cancer. “This is absolutely practice-changing” says Dr. Shruti Patel in this Science in Seconds. #pancan Read the abstract: https://bit.ly/4dChEWM

The latest from #ASCO26 Plenary: Ivonescimab + chemo yields superior OS vs tislelizumab + chemo in previously untreated advanced squamous NSCLC, per new results from the phase 3 HARMONi-6 trial conducted in China: https://bit.ly/49qr1WW #ASCODailyNews

Dr. Wolpin gets a well-deserved standing ovation at the plenary session of #ASCO26 for this K-M curve

Dr Fred Saad reports on PSMAddition subgroup analysis: 177Lu PSMA 617 + ADT + ARPI improves rPFS across mHSPC 📈 • Consistent benefit across disease volume and de novo/recurrent subgroups ✅ • Safety and PROs similar across groups #ProstateCancer #ASCO26 #Oncology #MedEd

Dr Kim N Chi shares PLUDO crossover analysis: 177Lu-PSMA-617 vs docetaxel in mCRPC 🔁 • No significant differences in rPFS or OS between sequences • Supports use of both therapies in patients progressing after ARPI #ProstateCancer #ASCO26 #Oncology #MedEd

At a median follow-up of 11.8 months (range, 1.1-21.9), median PFS and OS were 6.8 months (95% CI, 5.2-8.3) and 12.5 months (95% CI, 10.2-16.8), respectively... greater antitumor activity in participants [with previous] ICI and chemotherapy than what has been reported for paclitaxel or cetuximab.

In this exclusive set of First Look videos from #ASCODailyNews, Dr. Monty Pal of @cityofhope.bsky.social#ASCODailyNewsdiscusses each of the 5 Plenary abstracts before they're presented later today at #ASCO26: https://bit.ly/4dOUfA6

Apalutamide group VS placebo group with no evidence of disease at 4 years (21.9% vs. 18.3%; odds ratio, 1.25; P=0.04) After a median follow-up of 5 years, with an overall mortality of 8.5%, overall survival in the apalutamide group as compared with the placebo group, HR for death of 1.08

Looking forward to expert discussion on RAMPART. Interesting that monotherapy arm was negative. Side effects significant in double immunotherapy, but no meaningful difference in Qol? Note: 3 grade 5 events (deaths)in Adjuvant setting. #kidneycancer #kcsm #ASCO26

A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors. The interim results of the @swog.org S1823 (#CCTG GCC1) study presented at #ASCO26 could identify patients at higher risk of relapse earlier Presented by #DrLuciaNappi buff.ly/wLDl01S @vchresearch.bsky.social

Among patients with 𝘙𝘌𝘛 fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. Full phase 3 LIBRETTO-432 trial results: https://nej.md/3Q3QcIo #ASCO26

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://nej.md/4nWaxvM #ASCO26

I can attest to this reality And a lot of it comes from ... increasing documentation requirements "Scribe is help you document, so now you can document more"

New research from @atishchoudhury.bsky.social, MD, PhD, looks at whether treatment can be safely scaled back for certain patients with metastatic prostate cancer who responded exceptionally well to androgen receptor pathway inhibitor therapy. #ASCO26

Alicia Morgans, MD, MPH, reports that in the first randomized U.S. study of cognitive effects in advanced prostate cancer, darolutamide led to less decline in thinking and memory than enzalutamide over 24 weeks (n=111). #ASCO26

@AtishChoudhury @DanaFarber_GU reports #ADREAM, a trial of de-intensification for metastatic AR sensitive #prostatecancer. Median 2 years off tx — holding tx is feasible and could be an approach in excellent responders. Sets up #LIBERTAS trial & others. #ASCO26 @oncoalert @asco

meetings.asco.org/meetings/202... Plenary presentations upcoming tomorrow

🎯 Bezuclastinib + sunitinib cut the risk of disease progression or death by 50% vs sunitinib alone in advanced GIST after imatinib, with a median PFS of 16.5 vs 9.2 months and an ORR of 46% vs 26%. 📊🧬 Read more ➡️ www.onclive.com/view/bezucla... #GIST #ASCO26 #Oncology @ascocancer.bsky.social

Dr. Barbara Burtness shared updated results from KEYNOTE‑412 in unresected locally advanced #HNSCC. In pts with high PD‑L1 expression, adding pembro to CRT improved outcomes vs CRT alone. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

After lorlatinib, what comes next for ALK+ #lungcancer? New ASCO 2026 data on neladalkib - the Nuvalent trial - shows 31% response in heavily pre-treated patients, rising to 46% without prior lorlatinib. Early data, not yet approved. But a real signal. Abstract 8503 #ASCO26 #LCSM

This week, Dr. Brian Wolpin, a 2009 Conquer Cancer grant recipient, will deliver keynote updates on the #ASCO26 plenary stage to present findings on daraxonrasib, a targeted KRAS inhibitor that nearly doubled the median survival in advanced pancreatic cancer. Read more: https://bit.ly/49WSeRg

Rahul Banerjee, MD, FACP, previews the phase 3 SUCCESSOR-2 trial evaluating mezigdomide in combination with carfilzomib and dexamethasone, which will be presented at #ASCO26 #mmsm Read more on the most anticipated @ascocancer.bsky.social myeloma abstracts here www.onclive.com/view/frontli...

Phase 3 MajesTEC-9 trial: In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. https://nej.md/3PvpJDr #ASCO26

Phase 3 TALAPRO-3 trial: In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. https://nej.md/4nRSB5n #ASCO26 | @ascocancer.bsky.social#ASCO26

Ugandan children with sickle cell anemia who received 10 years of hydroxyurea therapy had sustained laboratory and clinical benefits, improved growth, and few toxic effects. Read the full summary of research findings: https://nej.md/4nRSBlT

In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. Full HERIZON-GEA-01 trial results are summarized in a new Quick Take. https://nej.md/4dPdxFs

In NSCLC with 𝘌𝘎𝘍𝘙 exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. Full phase 3 WU-KONG28 trial results: https://nej.md/4fQWMwa #ASCO26

Just presented at #ASCO26: TALAPRO-3 results show that combining talazoparib with enzalutamide improves outcomes over enzalutamide alone for men with HRR-altered mCSPC. #ASCODailyNews has more: https://bit.ly/430i3Mw

Here are the #ASCO26 sessions at a glance, 2-page view. Friday and Tuesday put together at the end, as they are shorter days and I can only include 4 images. Full document here: cdn.bfldr.com/KOIHB2Q3/as/...

🔜 #GU26 @ascocancer.bsky.social PFS benefit less than I would have expected… “The median (95% CI) PFS was 14.7 (11.7–21.3) mos among pts in the concomitant ARPI cohort vs 12.5 (11.5–13.6) months in the no concomitant therapy. Ongoing follow-up… on long-term clinical outcomes, including OS.”

At @ascocancer.bsky.social #GU26, Robert Motzer presented phase 3 trial results that showed belzutifan + lenvatinib achieved superior PFS & ORR compared with cabozantinib in people with advanced #kidneycancer who progressed after immunotherapy. @mskcancercenter.bsky.social#GU26#kidneycancer🔗 https://bit.ly/4r4AYPD

Promising news from #GU26: Research led by @drchoueiri.bsky.social#GU26shows that adding #belzutifan to pembrolizumab adjuvant therapy prevented #ccRCC recurrence in high-risk patients better than pembrolizumab alone. Learn more: https://bit.ly/3OxZdIE

EV + pembro in CisPt eligible pts KEYNOTE-B15/EV-304 study 24-mo estimated EFS rate 79.4% vs 66.2%; HR 0.53 24-mo estimated OS rate 86.9% vs 81.3%; HR 0.65, pCR rate (55.8% vs 32.5%) #GU26

New in the January 1, 2026, issue of NEJM: Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase 3 trial) nej.md/493hVjl Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated NSCLC (FLAURA2 phase 3 trial) nej.md/4opdBzC

At a median follow-up duration of 34.5 months, median PFS was unreached in the teclistamab–daratumumab group versus 18.1 months in the DPd or DVd group, with an estimated 36-month PFS of 83.4% versus 29.7% and an apparent plateauing of the curves beyond this landmark

In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg

In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy. Full RC48-C016 phase 3 trial results and Research Summary: nej.md/3W76VtS

Bishal Gyawali makes "a case for using superiority design to test de-escalation strategies. This will avoid the limitations of non-inferiority design and make de-escalation strategies more efficient to test."

At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7 #MedSky #Oncology

3️⃣ Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (EMBARK trial) nej.md/4h8QpDc 𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲: Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa

#ESMO25: Enzalutamide failed to deliver in high-risk localised #ProstateCancer in the ENZARAD trial, but improved OS, with leuprolide, in biochemically recurrent prostate cancer in the final OS analysis of EMBARK. #ESMODailyReporter➡️ https://ow.ly/XCPX50XeO8K Alison Tree

#ESMO25: 177Lu-PSMA-617 with ADT plus ARPI showed PFS benefit in hormone-sensitive #ProstateCancer (#HSPC) but no improvement seen with 177Lu-PSMA-617 vs docetaxel in castration-resistant prostate cancer (#mCRPC) after ARPI. #ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj#ESMO25#ProstateCancer

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study www.thelancet.com/journals/lan...

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial - The Lancet Oncology www.thelancet.com/journals/lan...

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC | New England Journal of Medicine www.nejm.org/doi/full/10....

Great result ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

#ESMO25: Atezolizumab prolonged DFS in #ctDNA+ muscle-invasive #BladderCancer in the IMvigor011 #ClinicalTrial, providing first evidence in support of minimal residual disease-guided adjuvant #immunotherapy in this setting. #ESMODailyReporter ➡️ https://ow.ly/ythW50XeYRP#ESMO25#ctDNA+

#ESMO25: Use of #ctDNA as a decision-making aid to guide adjuvant chemotherapy may not be ready for prime time in #ColonCancer as two #ClinicalTrials fail to meet their primary endpoints. Read more in the #ESMODailyReporter ➡️ https://ow.ly/OFmM50XeZaZ#ESMO25#ctDNA#ColonCancer#ClinicalTrials#ESMODailyReporter#LiquidBiopsy

#ESMO25: Phase III FORTITUDE-101 #ClinicalTrial reports improved short-term survival with first-in-class FGFR2b inhibitor bemarituzumab added to chemotherapy to treat FGFR2b-overexpressing #Gastric or #GEJCancer. More in the #ESMODailyReporter ➡️ https://ow.ly/C2MU50Xf08l#ESMO25